“Global Design Competition of Intelligent Life” Jinghai Tianjin, China, Is Grandly Opened
On November 18, the press conference of the “Global Design Competition of Intelligent Life”, jointly organized by the Jinghai District People’s Government of Tianjin, PRC., the Industrial Culture Development Center of MIIT of China, the Tianjin Municipal Committee Cyberspace Office, China, and the Tianjin Municipal Bureau of Industry and Information Technology of China, was held at the China National Convention Center in Beijing, signifying that the Competition is officially launched to accept entries worldwide.
With the theme “5G Intelligence Drawing Smart Life”, the “Global Design Competition of Intelligent Life” Jinghai Tianjin of China aims to present the Family Apartment area of the Jinghai Intelligent Industrial Park in Tianjin as a space for the application of 5G intelligent life. Following the key idea of “green, shared, interconnected, and innovative” design, a win-win and sharing platform is created by virtue of the Competition for the communication and cooperation associated with intelligent life to satisfy the needs of high-level talents in the innovation and business starting field for their family life in the future, and promote the extensive integration of intelligent technology into their everyday life. Additionally, a community will be fostered as an example of intelligent life to lead its development in China and then win a global reputation, so as to make Jinghai Tianjin of China an industrial demonstration district for intelligent life in the world.
The task list for the Competition contains 28 design tasks in three categories – namely, intelligent community building design, intelligent design, and operational mode design. The Competition receives the intelligent life solutions submitted by the world-renowned architectural design studios and intelligent life solution providers, and encourages the application of innovative ideas and digital technology in the design while keeping good predictability, scalability, iteration and operability, and highlighting easy application, easy identification, and security. Meanwhile, investment estimation and cost effectiveness are significant factors considered in the review of entries. The Competition is divided into three stages, including entry registration, qualification review, and final review. It is expected to organize the final review in the middle of April 2020, and hold the award ceremony of the “Global Design Competition of Intelligent Life” to present 1 first prize, 2 second prizes, and 3 third prizes. A recognition award will be granted to the design teams of the other entries in the final.
As one of the 5G pilot cities in China, Tianjin has held the Global Intelligent Competition for three consecutive years since 2017. In this way, it is embracing the new era of intelligence, developing the new economy of intelligence, and nurturing the new life of intelligence with its vanguard arms stretched out wider, so as to speed up the development of “Tianjin Intelligent Port”.
Abutting Xiong’an New Area and Binhai New Area (Tianjin), Jinghai District of Tianjin City is a great place for investment and development thanks to its unique geographical location and advantageous resources. In recent years, Jinghai District is thoroughly implementing and carrying out the Development Planning of the State Council for a New Generation of Artificial Intelligence and the related requirements of Tianjin Municipal Committee and Municipal Government for the construction of intelligent city. Relying on the Jinghai Intelligent Industrial Park, it is dedicated to developing a new highland, a high-end clustering area, and an application demonstration area for global intelligent industry, so that the economy will be stimulated by intelligence.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191124005061/en/
Contact information
Emma Bu
86 15822544775
https://www.gidcontest.com/
service@gidcontest.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom